title: [Pulsatilla decoction treat inflammatory bowel disease by activating NLRP3].
abstract: OBJECTIVE
  To investigate the molecular mechanisms underlying the treatment of inflammatory bowel disease (IBD) by Pulsatilla decoction.
  
  
  METHODS
  84 BALB/c mice were randomly divided into ethanol control group, model group, SASP group, Pulsatilla decoction group (further divided into low, middle and high dose group) and zVAD group (n = 12). Intragastric and celiac drug administration were used in each group respectively. The expression of NLRP3, ASC, Caspase-1, IL-18 and IL-1beta in the colons were detected by fluorescence quantitative RT-PCR, Elisa and immunohistochemistry after treatment respectively.
  
  
  RESULTS
  Compared with the model group, SASP group, middle and high dose group could treat IBD effectively (P < 0.01), while this effect was restrained in zVAD group (P < 0.05). In the meantime, middle and high dose group could effectively raise the expression of NLRP3, ASC, Caspase-1, IL-18 and IL-1beta in the colons (P < 0.05), while this effect was also inhibited in zVAD group (P < 0.05).
  
  
  CONCLUSIONS
  Pulsatilla decoction is likely to exert their therapeutic effect by activating NLRP3 inflammasome which further promote the formation of the corresponding inflammation factors such as 1L-18 and IL-1beta.
authors: The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China. homergates@qq.com
authors: Zhen-Lei
authors: ZL
authors: Wang
authors: Ping-Ping
authors: PP
authors: Sun
authors: Tian-Xiao
authors: TX
authors: Li
authors: Shu-Xia
authors: SX
authors: Li
mesh_terms: D000818:Animals; D002352:Carrier Proteins / Q000235:genetics / Q000378:metabolism*; D020170:Caspase 1 / Q000235:genetics / Q000378:metabolism; D016207:Cytokines / Q000235:genetics / Q000378:metabolism*; D004195:Disease Models, Animal; D004365:Drugs, Chinese Herbal / Q000494:pharmacology* / Q000627:therapeutic use; D058847:Inflammasomes / Q000378:metabolism; D015212:Inflammatory Bowel Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D020382:Interleukin-18 / Q000235:genetics / Q000378:metabolism; D053583:Interleukin-1beta / Q000235:genetics / Q000378:metabolism; D007413:Intestinal Mucosa / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D000071199:NLR Family, Pyrin Domain-Containing 3 Protein; D008517:Phytotherapy; D031946:Pulsatilla / Q000737:chemistry*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D011897:Random Allocation; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013411:Sulfadiazine / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D002352:Carrier Proteins; D016207:Cytokines; D004365:Drugs, Chinese Herbal; D058847:Inflammasomes; D020382:Interleukin-18; D053583:Interleukin-1beta; D000071199:NLR Family, Pyrin Domain-Containing 3 Protein; C492716:Nlrp3 protein, mouse; D012333:RNA, Messenger; D013411:Sulfadiazine; D020170:Caspase 1